reports
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Product...
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility The agreement would facilitate providing Tevogen Bio with in-house cell therapy production capabilitiesFormalized agreement aligns with previously announced topline forecasts WARREN, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced it has entered into an agreement with CD 8 Technology Services LLC (“CD8”) for the development and/or acquisition of a turn-key facility that is intended to support both in-house pre-clinical research and GMP cel...
Tevogen Bio Commissions Databricks to Accelerate Development of Predic...
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction WARREN, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced the commission of Databricks, Inc., a leader in data, analytics and artificial intelligence (AI), with an aim to accelerate the development of PredicTcell, the Company’s proprietary AI-driven target prediction model for precision immunotherapy. Databricks will provide a dedicated data engineering team and its expertise in building, scaling, and govern...
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Ada...
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in . Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at . Along with Dr. Ryan Saadi, the panel will also...
Tevogen Announces Tevogen Generics, a New Effort in Support of Preside...
Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announces its newest effort: Tevogen Generics. This effort is in response to the growing national focus on pharmaceutical affordability and coincides with the recent tariff-related statements from President Donald Trump. To lead the launch of Tevogen Generics, the Company has expended responsibilities of its Chief Commercial Offic...
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Ev...
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs WARREN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), a healthcare company with dedicated efforts in immunotherapy and artificial intelligence, today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, presented at AI x Bio Philly, a premier event highlighting the convergence of artificial intelligence and life sciences in the Philadelphia region. Hosted by BioBuzz, BitsInBio, Atria, and Zetta, AI...
Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Managemen...
Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission WARREN, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), a healthcare company with dedicated efforts in immunotherapy and artificial intelligence, is unified by a commitment to advancing patient-centric solutions. The Company’s clinical-stage immunotherapy effort, Tevogen Bio, focuses on the development of off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers. Its artificial intelligenc...
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company ...
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 Health Care Power List by NJBIZ. This recognition highlights Dr. Saadi’s leadership and commitment to advancing healthcare innovation and acc...
Tevogen Bio Appoints David E. Banko as Global Head of Government Affai...
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role...
Tevogen Bio Announces Unique T Cell Vaccine Under Development and File...
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company’s lead product candidate TVGN 489, to mitigate the risk posed by mutations.Approach may provide prophylaxis to viral infections and would be complementary to current treatment under development by Tevogen Bio.Powered by Tevogen Bio’s artificial intelligence initiative, Tevogen.AI.The company hopes to address public concerns about inoculation during vaccine development...
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker...
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel WARREN, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- Mittul Mehta, Chief Information Officer & Head of Tevogen.AI at (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech company, recently joined industry leaders at Proskauer’s AI discussion panel, "Attuned AI: Shaping AI to Empower Your Industry," held on March 6, 2025, in New York City. Along with Mittul Mehta, the event featured Brooker Belcourt, General Manager of Finance from Perple...
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reite...
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations Tevogen Bio will receive the remaining $8 million grant, totaling $10 million, from KRHP LLC this quarter, following a positive review of its progress, particularly in Tevogen.AI.Efficient operations with operating expenses of $9.7 million for the first three quarters of 2024.The company's AI division has advanced its PredicTcell platform using expanded datasets and wet lab science to enhance predictive modeling capabilities. WARREN, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Hol...
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 1...
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell therapies.The company’s ExacTcell™ technology enabled a proof-of-concept trial with highly positive results, published in Blood Advances.A key step in making therapies more accessible was the launch of Tevogen.AI and a partnership with Microsoft. WARREN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), a clinical-stage ...
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Pe...
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned 600% higher market cap per team member when compared to industry average. Source: .Current ownership breakdown: Insiders 79%; Independent Board Members 1%; Lead Investor 7%; SPAC Sponsor 6%; Others 8%.Assets believed to be valued in the billions. (Not reflected on Tevogen’s balance sheet as internally developed intangible assets are generally not permitted to be capitalized as per US GAAP).Additional business updates to follow in coming days. WARREN, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE)...
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital a...
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech company, reaffirms his commitment to preserving equity for shareholders. Amid ongoing discussions about financing approaches in the biotech sector, Dr. Saadi emphasizes his distinct strategy, which prioritizes efficiency, asset ownership, and a path to revenue. “I’m not opposed to the concept of equity financi...
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of ...
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company’s 2024 financing activity at the one year anniversary of being listed on the Nasdaq exchange. , Tevogen Bio signed a letter of intent with CD8 Technology Services to build an up to $50 million turn-key research and development facility for Tevogen Bio’s use. ...
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on th...
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech company, today issued a statement from its Founder and CEO, Nobel Peace Prize nominee Dr. Ryan Saadi, regarding broader implications of short-selling. “Tevogen Bio is committed to advancing innovative medical solutions while maintaining affordability for patients, a mission that is essential for sustainable healthcare innovation. Since ...
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary...
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans WARREN, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech company, congratulates Robert F. Kennedy Jr.’s as he begins his role at the head of Health and Human Services. Secretary Kennedy and the administration’s collective goal of achieving accessibility to affordable healthcare in the U.S. aligns with Tevogen ...
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges w...
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation WARREN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), is a clinical-stage specialty immunotherapy biotech company. As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio’s innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare. With the concern of Chinese pharmaceutical companies developing drugs at...
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Techno...
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure WARREN, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical Advanced Research and Development Authority (BARDA) TechWatch team. The discussion focused on Tevogen Bio’s affordable and scalable ExacTcell technology, the positive results of its proof-of-concept (POC) clinical trial for TVGN 489, the use of Artificial Intelligence in its...
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilut...
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding The grant funding will further Tevogen Bio’s mission to develop therapies for treatment of cancers and viral infections.Tevogen Bio may also utilize the grant funding to further expand its artificial intelligence effort.This grant is in addition to the previously announced $36 million loan agreement from 2Q24. WARREN, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech, announced it may receive up to $10 milli...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.